Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Vor Biopharma

Main focus: Cell therapies for cancer treatment

Company stage: Clinical

Diseases: Acute myeloid leukaemia (AML)

Genome editing tool: CRISPR-Cas9

Funding stage: Public (NASDAQ:VOR)

Location: Cambridge, MA, USA



Partners: Metagenomi

Vor Biosciences is a clinical-stage cell therapy company, with a focus on delivering innovate medicines against cancer, with a primary focus on acute myeloid leukaemia. The company uses its proprietary Vor platform to discover novel targets such as CD123 and CLL-1. The company also uses the platform to discover new targets for non-myeloid malignancies. The company is focused on developing engineered haematopoetic stem cells (eHSC) and CAR-T cells as well as a synergetic treatment using a combination of the two technologies.


HashtagVor Biopharma

Company: Vor Biopharma
Search CRISPR Medicine